Skip to main content
. Author manuscript; available in PMC: 2021 Oct 3.
Published in final edited form as: N Engl J Med. 2020 Dec 31;383(27):2639–2651. doi: 10.1056/NEJMoa2020248

Table 2.

Primary Composite Outcome and Components of the Primary Composite Outcome at 2 Years.*

Outcome Higher Hemoglobin Threshold (N = 845) Lower Hemoglobin Threshold (N = 847) Adjusted Relative Risk (95% CI) P Value
no. of infants/total no. (%)
Primary outcome: death or neurodevelopmental impairment 423/845 (50.1) 422/847 (49.8) 1.00 (0.92–1.10) 0.93
Components of primary outcome
 Death 146/903 (16.2) 135/901 (15.0) 1.07 (0.87–1.32)
 Neurodevelopmental impairment 277/699 (39.6) 287/712 (40.3) 1.00 (0.88–1.13)
  Cognitive delay 269/695 (38.7) 270/712 (37.9) 1.04 (0.91–1.18)
  Moderate or severe cerebral palsy§ 48/711 (6.8) 55/720 (7.6) 0.87 (0.60–1.26)
  Severe vision impairment 5/713 (0.7) 6/720 (0.8) 0.83 (0.25–2.76)
  Severe hearing impairment 14/710 (2.0) 25/715 (3.5) 0.56 (0.29–1.07)
*

The relative risk was adjusted for birth-weight and center stratum. The P value is reported only for the composite primary outcome. For the secondary outcomes, 95% confidence intervals (CIs) were not adjusted for multiplicity and should not be used to infer definitive treatment effects.

Infants with incomplete follow-up but with known vital status were included in these numbers. Five infants in each group had unknown vital status at the start of the 2-year follow-up window.

Cognitive delay was defined as a composite cognitive score of less than 85 (1 SD below the mean of 100) on the Bayley Scales of Infant and Toddler Development (BSID-III), third edition; scores range from 55 to 145, with higher scores indicating better performance.10

§

Moderate or severe cerebral palsy was defined as a Gross Motor Function Classification System level II or higher (levels range from I [mild impairment] to V [most severe impairment]). Level II denotes moderate cerebral palsy with a limited ability to walk. Levels III to V indicate increasing severity of gross motor impairment.

Trial centers with low incidences of blindness or hearing impairment were pooled with their nearest geographic center before estimation of adjusted relative risks.